25.46
+3.15(+14.12%)
Currency In USD
| Previous Close | 22.31 |
| Open | 22.48 |
| Day High | 25.57 |
| Day Low | 22.23 |
| 52-Week High | 25.57 |
| 52-Week Low | 7.65 |
| Volume | 92,680 |
| Average Volume | 44,563 |
| Market Cap | 540.2M |
| PE | -1.12 |
| EPS | -22.75 |
| Moving Average 50 Days | 17.71 |
| Moving Average 200 Days | 12.37 |
| Change | 3.15 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $75.37 as of December 04, 2025 at a share price of $25.46. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $323.92 as of December 04, 2025 at a share price of $25.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
GlobeNewswire Inc.
Nov 10, 2025 12:30 PM GMT
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 c
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two ab
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lye